Isis executes

Isis Pharmaceuticals Inc. has planted a second pillar in its strategy of pursuing expansive long-term relationships that combine its antisense capabilities with the scientific and clinical expertise of its partners.

On Aug. 3, the company unveiled its second strategic partnership, under which Isis and AstraZeneca plc will work to discover and develop antisense therapeutics for cardiovascular, metabolic and renal diseases. The goal is to open new target space...